Fatty acid profiles of Antarctic cyanobacteria Leptolyngbya

Antarctic cyanobacteria may represent a potential resource of new and unique compounds with interesting capabilities. Profiling of fatty acids in Antarctic cyanobacteria can provide an overview of potential fatty acids present in them, that can be utilised in future applications

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Characterisation of hybrid gold-polymer nanoparticles for use in bioassays

A series of novel gold-polymer nanoparticles that have been encoded with a SERS-active Raman molecule known as a 'Raman tag', have been synthesised. This study has demonstrated that using polymers with dithiocarbamate containing end groups, nanoparticles can be readily coated by using a phase transfer method. Thus far, two SERS-active molecules have been assessed for suitability as Raman tags. These molecules are rhodamine B isothiocyanate and fluorescein isothiocyanate. These hybrid nanoparticles have been characterized using SERS, TEM and UV-Vis spectroscop

The facial soft tissue simulation of orthognathic surgery using biomechanical model

This paper describes a surgical planning, simulation and prediction of facial soft tissue appearance with regard to the orthognathic surgery. The facial soft tissue prediction is done by means of mandibular advancement through the osteotomy planning system. Our approach is based on finite element method on 3D facial models of quadrilateral elements. These elements represent different tissue regions of facial bone and skin surface semi-automatically generated from segmented patient-specific computer tomography data. We describe the surface facial model reconstruction from individualized anatomy, surgical procedures and numerical solution for static postoperative facial appearance using linear elastic finite element analysis. The physical computational modeling for the prediction of soft tissue is described. Isotropic, homogeneous and linear elastic tissue models are elaborated. The simulated result which is achieved by the advancement of lower jaw bone through the contact analysis is presented. Discussion on evaluation of the simulated result is performed with the actual findings